To value the late genitourinary (GU) morbidity in men treated with a hypofractionated radiotherapy regimen for prostate cancer. Patients with intermediate risk factors according to D'Amico's criteria were selected. The hypofractionated schedule consisted of 15 fractions of 3.63 Gy delivered three times per week for a total dose of 54.3 Gy. Significant changes in storage-symptoms were not found. A significant transient worsening in the score of late effects of normal tissue late effects normal tissue task force (LENT)-subjective, objective, management, analytic (SOMA) urinary-function domain was observed at 12 months with subsequent improvement at 28 months. The assessment of voiding-symptoms and maximum urinary flow rate (Qmax) showed that no significant difference was measurable at 12 and 28 months. For PVR, a transient increase at 12 months with a subsequent decrease at 28 months was measured. No significant increase in alphablockers usage and in the percentage of men with pathological nonintubated uroflowmetry (NIF) was observed at 12 and 28 months. Finally, patients did not perceive any clinical worsening in their quality of life (QoL) as attested by the International Prostate Symptom Score (IPSS)-QoL. Our study seems to suggest that our hypofractionated radiotherapy schedule for the treatment of prostate cancer is safe in terms of late urinary morbidity. Further study will be required to confirm our results.
Introduction
Although modern three-dimensional (3D) conformal radiotherapy has allowed to reach a total dose that increases local control with acceptable treatment toxicity, 1,2 each of these treatments can produce bowel, bladder and sexual dysfunction that can negatively interfere with the quality of life (QoL).
Recent evidences 3 indicate that the a/b ratio for prostate cancer may be lower than what was thought previously. Although there appears to be an increasing consensus on a low a/b ratio value in prostate cancer, the often quoted value of 1.5 Gy may not be appropriate and several studies have concluded that this value might be in the range of 1.0-3.0. 4, 5 However, this is still the subject of much debate. 6, 7 In addition, it is has been suggested that treatment schedules relying on fewer, larger daily fractions of radiotherapy may increase the therapeutic ratio. Such findings have renewed interests in using hypofractionated radiotherapy treatment in prostate cancer. Early results from several uncontrolled trials indicate that, schedules that rely on larger daily doses are associated with low toxicity and comparable biochemical relapse-free survival rates. [8] [9] [10] At present the main concern is the uncertainty about late normal-tissue toxicity of such hypofractionated protocols. Late normaltissue reactions are more dependent on the dose per fraction of irradiation than acute reactions. In terms of toxicity, late rectal toxicity has been the subjects of an intense investigation, whereas less attention has been paid to urinary toxicity and much more research is needed on this topic. Although in terms of urinary toxicity acceptable levels of morbidity after radiotherapy (brachytherapy and/or external beam) have been reported, the treatment of localized prostate cancer with these techniques may be complicated by the development of lower urinary tract symptoms (LUTS).
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In addition, a population of men who might develop persistent, bothersome symptoms that may be largely refractory to conventional medical treatments exist. Clinical data in terms of late toxicity after hypofractionated protocols are sparse and much more research is needed on this topic.
With this background in mind, a hypofractionated schedule has been instituted aiming to assess the survival benefit, as well as the morbidity associated with this schedule. Patients eligible for the study were those with intermediate risk factors according to D'Amico's criteria. The hypofractionated schedule consisted of 15 fractions of 3.63 Gy delivered three times per week for a total dose of 54.3 Gy in association with 6 months of hormonal therapy (HT). 12 This paper is focused exclusively on the analysis of late urinary morbidity measured by subjective and objective instruments.
Materials and methods

Study population
Patients with intermediate risk factors according to D'Amico's criteria were selected. The radiological tests (bone scan and/or pelvic TC/or magnetic resonance imaging) if ordered, were required to be negative for metastases. Patients were staged according to American Joint Committee on Cancer 2002 criteria. All patients received 6 months of HT. 12 HT was initiated 3 months before radiotherapy and consisted of a luteinizing hormone-releasing hormone (LHRH) agonist (Leuprolide acetate) and a non-steroidal antiandrogen (Bicalutamide). Luteinizing hormone-releasing hormone agonist was delivered intramuscularly every 3 months at the dose of 22.5 mg. Bicalutamide was taken orally at the dose of 50 mg.
Radiation therapy
Computed tomography-imaging (CT)-based simulations were routinely carried out, and a treatment planning was carried out during HT. Bladder and rectum were contoured on all patients according to Radiation Therapy Oncology Group guidelines. 13 All patients were treated with 6-15 mV photon beams. About 2 h before the simulation or treatment, the patients were advised to urinate and to take 500 ml of water, to have a comfortable full bladder. Three-dimensional conformal techniques were used. Almost five beams were selected to obtain acceptable dose distribution in all patients. All patients were treated by the same hypofractionated schedule to a total dose of 54.3 Gy in 15 fractions of 3.62 Gy delivered three times per week. For each patient, two clinical target volumes (CTVs) were defined. CTV1 included both prostate and seminal vesicles, whereas CTV2, contained the prostate alone. The planning target volume 1 (PTV1) was grown from CTV1 using an expansion of 8 mm in all directions except posteriorly, where a 6 mm margin was used. The risk of seminal vesicle involvement was assessed by Diaz's formula.
14 A risk 415% was considered to be the threshold 14 for their inclusion in the treatment volume. All patients presented a risk of seminal vesicle involvement greater than 15%. In our institution a dose of 55-65 Gy in conventional regimen 15 is used in presence of a risk of seminal vesicle involvement 415%. Therefore, the aim was to treat the CTV1 at a dose of 43.4 Gy in 12 fractions (biologically equivalent to 63.5 Gy assuming an a/b ratio of 1.5 Gy or 57.5 Gy assuming an a/b ratio of 3 Gy), whereas for CTV2 the intended dose was 54.3 Gy in 15 fractions (biologically equivalent to 79.4 Gy assuming an a/b ratio of 1.5 Gy or 71.9 Gy assuming an a/b ratio of 3 Gy). The total dose was prescribed to the isocenter, with the 95% isodose volume surrounding the PTVs. The risk of lymph node involvement was determined according to the equation %rLD ¼ (2/3 iPSA þ [(GSÀ6) Â 10]. A risk X15% was considered to be the threshold for their inclusion in the volume treatment. No patient had a risk X15% and the lymph node irradiation was not carried out. In our institution for conventionally fractionated regimen, the constraints are V65o17% and V40o35% for rectum, and V65o25% and V40o50% for bladder. For the hypofractionated regimen the constraints were V49o17% and V30o35% for rectum, and V49o25% and V30o50% for bladder. The derivation of V49 Gy and V30 Gy were based on the assumption of the a/b ratio for late effects of 3 Gy.
Follow-up
Patients were assessed at baseline and weekly during radiotherapy. All measures of genitourinary (GU) morbidity were assessed 1 week before the beginning of HT (baseline). This was done to avoid the effects of this therapy on the GU symptoms at baseline. Subsequently, patients were assessed at 4 and 12 weeks after radiotherapy, 16 and every 3 months thereafter.
Outcome measures
Storage symptoms Patient perception of bladder condition (PPBC).
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Voiding symptoms Four voiding items of the International Prostate Symptom Score (IPSS).
Nonintubated uroflowmetry (NIF) Late effects normal tissue task force (LENT)-subjective, objective, management, analytic (SOMA) urinary-function domain International Prostate Symptom Score-quality of life (IPSS-QoL)
Terminology used was conform to the definitions recommended by the International Continence Society. 18 
Study outcomes
The late GU morbidity was estimated by measuring the changes from baseline (pre-radiotherapy (RT)) to month 28 in PPBC, voiding symptoms, IPSS-QoL, NIF (maximum urinary flow rate (Qmax) and PVR) and LENT/ SOMA urinary-function domain. The percentage of men with abnormal NIF and in treatment with -blockers at 12 and 28 months after radiotherapy was also quantified. GU morbidity resolution was defined as the return to within 20% of the pre-radiotherapy urinary symptoms. Any worsening above this cut-off was considered as clinically significant.
Statistical methods
The sample size of the study was estimated to achieve a 90% power for rejection of the null hypothesis that a greater than 20% difference in the baseline to endpoint (month 28) worsening in GU morbidity would be found LENT/SOMA urinary function LENT/SOMA urinary-function scores for all 51 patients were analyzed ( Table 2 
Objective measures of voiding difficulties
The assessment of Qmax, which showed no significant worsening with respect to baseline [ Radiotherapy and urinary morbidity V Tombolini et al increase in -blockers usage was not observed at 12 and 28 months (P ¼ 0.079) ( Table 3) . As an overall objective measure of voiding difficulties, the percentage of men with abnormal NIF were also quantified at 12 and 28 months after radiotherapy (Table 4 ). Significant increase in the percentage of men with pathological NIF at 12 (78.4%) (P ¼ 0.063) and 28 months (62.7%) (P ¼ 0.50) was not observed. A significant decrease in this percentage of men with abnormal NIF was observed at 28 months with respect to 12 months (P ¼ 0.031).
IPSS-QoL
As reported in Table 5 , the score of IPSS-QoL remained unchanged after radiotherapy. At baseline the mean score was 3.36 (3.09-3.62), whereas 12 and 28 months after radiotherapy the mean score was 3.55 (3.34-3.76) and 3.50 (3.25-3.75) (P ¼ 0.103).
Discussion
The success of cancer therapy has traditionally been measured by survival disease-related end points. More recently, patients and physicians have become aware of the morbidities associated with the treatment options for prostate cancer and now view treatment related morbidity as an outcome that, in addition to quantify life, warrants individual assessment. 19 The recent evidence 3 that the a/b ratio for prostate cancer may be in the range of 1.0-3.0 has renewed interests in using hypofractionated radiotherapy for the treatment of men with localized prostate cancer. Overall, the treatment of prostate cancer with radiotherapy may be complicated by the development of lower urinary-tract symptom and a subset of men who develop persistent, bothersome symptoms often are refractory to conventional medical treatments. Although lower urinary-tract symptom is not life-threatening it significantly impairs the QoL of patients and can have a deleterious effect on various domestic, occupational and psychosocial aspect of daily living. 11 Brenner 20 suggested that hypofractionation for prostate cancer appears to be as efficacious as standard fractions, more convenient for the patients in terms of logistics and acute morbidity, and less resource demanding than standard fractionation. However, the main concern is the uncertainty about late normal-tissue toxicity. Although clinical results from uncontrolled trials indicate that hypofractionated schedules are associated with low toxicity, [8] [9] [10] clinical data in terms of late toxicity are still sparse. In the current paper, we carry out an extensive analysis of the late urinary morbidity after hypofractionated radiotherapy schedule. To our knowledge, this is one of the first reports that describe, in an extensive way and with different measures, the urinary morbidity at 28 months after hypofractionated radiotherapy schedule for the treatment of prostate cancer. The analysis was conducted on a population of men with clinically localized prostate cancer. One of the strengths of our data is the number of different instruments used to assess urinary morbidity. In some measure, the individual instruments differ among them and measure specific aspects of GU morbidity. In addition, a further strength of our data is that the analysis of morbidity has been conducted by using a pre-and post-test experimental design. This study protocol is an attractive model for the assessment of morbidity before and after a treatment, as the comparisons are made 'within subjects' rather than 'between subjects'. In any research design, ideally, the experimenters could attempt to control all outside variables except for the one(s) to be measured, we believe that there is no better control than oneself. Although a direct comparison with other reports is made difficult by different measures used to assess urinary morbidity, our results seem to confirm that hypofractionated schedule in association with short-term HT is relatively safe in men with intermediate risk prostate Radiotherapy and urinary morbidity V Tombolini et al cancer. Significant changes were not found at 28 months in PPBC, LENT/SOMA urinary-function domain, voiding domain of IPSS and in objective measures, such as Qmax, and the percentage of men in treatment with alphablockers and with normal NIF after radiotherapy. The lack of changes in these subjective and objective measures was associated with a good perception of the QoL related to urinary morbidity as attested by the measure of IPSS-QoL analyzed at 12 and 28 months of follow-up.
Although an overall equivalence in terms of urinary morbidity was observed after radiotherapy with respect to baseline, some transient changes were measured for specific variables. A transient worsening in the PVR was observed at 12 months with a following improvement at 28 months. Although the minimally important difference in PVR that could be considered meaningful for a patient after radiotherapy has not been established, the worsening in this measure was not associated with a contextual significant worsening in Qmax, as well as in the percentage of men in treatment with alpha-blockers. Finally, a transient worsening of score in LENT/SOMA urinary function was measured after 12 months. However, the lack of changes in an overall objective measure of voiding difficulties, such as the percentage of men with abnormal NIF, seems to suggest that the transient worsening in PVR may be of no clinical value. Our results should be analyzed in light of the potential limitations that the study has. The facts that nearly one-third of the study population was in treatment before and during radiotherapy with alpha-blockers, that all men received a short course of HT and that treatment planning was carried out during HT might have modified the pattern of urinary morbidity. In addition, it has been suggested that the selection of men with a pre-radiotherapy PVR less than 100 ml may be associated with rapid IPSS resolution. 21 It should be noted that in our cohort all men had a PVR at baseline less than 100 ml. Finally, the relatively low number of patients might be another cause of bias in our study. However, the use of a pre-and posttest experimental design may have mitigated this bias, allowed us to maintain a good statistical power.
Conclusions
In conclusion our study seems to suggest that the proposed hypofractionated regimen in association with short course of HT is safe in terms of late urinary morbidity. However, the generalization of our results should be interpreted conservatively because of the observational nature of the study. Further study will be needed to confirm our results.
